The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1716
ISSUE1716
November 25, 2024
Drugs for Asthma
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Drugs for Asthma
November 25, 2024 (Issue: 1716)
The goal of asthma treatment is to control symptoms,
prevent exacerbations, and maintain normal lung
function. Management of acute exacerbations in the
emergency department is not discussed here.
- Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC). 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol 2020; 146:1217. doi:10.1016/j.jaci.2020.10.003
- Global Initiative for Asthma. Global strategy for asthma management and prevention, 2024. (Updated May 2024). Available at: www.ginasthma.org. Accessed November 6, 2024.
- Airsupra: an inhaled albuterol/budesonide combination for asthma. Med Lett Drugs Ther 2024; 66:41.
- DG Rayner et al. Inhaled reliever therapies for asthma: a systematic review and meta-analysis. JAMA 2024 October 28 (epub). doi:10.1001/jama.2024.22700
- JK Mukker et al. Ciclesonide: a pro-soft drug approach for mitigation of side effects of inhaled corticosteroids. J Pharm Sci 2016; 105:2509. doi:10.1016/j.xphs.2016.05.004
- I Axelsson et al. Inhaled corticosteroids in children with persistent asthma: effects of different drugs and delivery devices on growth. Cochrane Database Syst Rev 2019; 6:CD010126. doi:10.1002/14651858.cd010126.pub2
- R Beasley et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med 2019; 380:2020. doi:10.1056/nejmoa1901963
- J Hardy et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet 2019; 394:919. doi:10.1016/s0140-6736(19)31948-8
- ED Bateman et al. Positioning as-needed budesonide-formoterol for mild asthma: effect of prestudy treatment in pooled analysis of SYGMA 1 and 2. Ann Am Thorac Soc 2021; 18:2007. doi:10.1513/annalsats.202011-1386oc
- R Beasley et al. Evaluation of budesonide-formoterol for maintenance and reliever therapy among patients with poorly controlled asthma: a systematic review and metaanalysis. JAMA Netw Open 2022; 5:e220615. doi:10.1001/jamanetworkopen.2022.0615
- W-C Huang et al. Comparison of budesonide/formoterol versus fluticasone furoate/vilanterol as maintenance and reliever therapy for asthma control: a real-world observational study. BMC Pulm Med 2024; 24:374. doi:10.1186/s12890-024-03190-8
- LA Lee et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med 2021; 9:69. doi:10.1016/s2213-2600(20)30389-1
- In brief: Neuropsychiatric events with montelukast. Med Lett Drugs Ther 2020 62:65.
- D Thomas et al. Effect of azithromycin on asthma remission in adults with persistent uncontrolled asthma: a secondary analysis of a randomized, double-anonymized, placebo-controlled trial. Chest 2024; 166:262. doi:10.1016/j.chest.2024.02.048
- SL Rhoads and A Mohan. A novel examination of azithromycin as a low-cost intervention to achieve remission in asthma. Chest 2024; 166:241. doi:10.1016/j.chest.2024.06.003
- NA Hanania et al. Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma. World Allergy Organ J 2022; 15:100695. doi:10.1016/j.waojou.2022.100695
- M Humbert et al. Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients. Eur Respir J 2022; 60:2103130. doi:10.1183/13993003.03130-2021
- HA Farne et al. Anti-IL-5 therapies for asthma. Cochrane Database Syst Rev 2022; 7:CD010834. doi:10.1002/14651858.cd010834.pub4
- A Bourdin et al. Matching-adjusted comparison of oral corticosteroid reduction in asthma: systematic review of biologics. Clin Exp Allergy 2020; 50:442. doi:10.1111/cea.13561
- KR Chapman et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy 2019; 74:1716. doi:10.1111/all.13850
- DJ Jackson et al. Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype. N Engl J Med 2024 September 9 (epub). doi:10.1056/nejmoa2406673
- ME Wechsler et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med 2022; 10:11. doi:10.1016/s2213-2600(21)00322-2
- LB Bacharier et al. Dupilumab in children with uncontrolled moderate-to severe asthma. N Engl J Med 2021; 385:2230. doi:10.1056/nejmoa2106567
- LB Bacharier et al. Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study. Lancet Respir Med 2024; 12:45. doi:10.1016/s2213-2600(23)00303-x
- A Menzies-Gow et al. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. Lancet Respir Med 2023; 11:425. doi:10.1016/s2213-2600(22)00492-1
- ID Pavord et al. Baseline FeNO independently predicts the dupilumab response in patients with moderate-to-severe asthma. J Allergy Clin Immunol Pract 2023; 11:1213. doi:10.1016/j.jaip.2022.11.043
- JA Bernstein et al. Real-world unified airway benefits of mepolizumab: effectiveness in patients with asthma and comorbid nasal polyps. Ann Allergy Immunol 2024; 133:422. doi:10.1016/j.anai.2024.06.033
- HK Mandl et al. Current and novel biologic therapies for patients with asthma and nasal polyps. Otolaryngol Clin North Am 2024; 57:225. doi:10.1016/j.otc.2023.08.006
- F Liao et al. Morning versus evening dosing of sublingual immunotherapy in allergic asthma: a prospective study. Front Pediatr 2022; 10:892572. doi:10.3389/fped.2022.892572
- R Chaudhuri et al. Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials. Lancet Respir Med 2021; 9:457. doi:10.1016/s2213-2600(20)30408-2
- H Wang et al. Asthma in pregnancy: pathophysiology, diagnosis, whole-course management, and medication safety. Can Respir J 2020; 2020:9046842. doi:10.1155/2020/9046842
- J Naftel et al. An international consensus on the use of asthma biologics in pregnancy. Lancet Respir Med 2024 August 28 (epub). doi:10.1016/s2213-2600(24)00174-7
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Asthma
Article code: 1716a
Article code: 1716a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.